Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-16
2011-08-16
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S116000
Reexamination Certificate
active
07998958
ABSTRACT:
Disclosed are novel gamma secretase inhibitors of the formula:Also disclosed are methods for inhibiting gamma secretase, for treating one or more neurodegenerative diseases, for inhibiting the deposition of beta amyloid protein, and for treating Alzheimer's disease using the compounds of formula (I).
REFERENCES:
patent: 5646167 (1997-07-01), MacPherson et al.
patent: 6683091 (2004-01-01), Asberom et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 7122675 (2006-10-01), Josien et al.
patent: 7208602 (2007-04-01), Pissarnitski et al.
patent: 7256186 (2007-08-01), Pissarntiski et al.
patent: 7368457 (2008-05-01), Josien
patent: 2004/0171614 (2004-09-01), Pissarnitski et al.
patent: 2005/0239796 (2005-10-01), Thurieau et al.
patent: 2006/0004004 (2006-01-01), Asberom et al.
patent: 2006/0009467 (2006-01-01), Josien et al.
patent: 2006/0100427 (2006-05-01), Pissarnitski et al.
patent: 2007/0197581 (2007-08-01), Asberom et al.
patent: 2802206 (2001-06-01), None
patent: 4-247081 (1992-09-01), None
patent: WO 99/62888 (1999-12-01), None
patent: WO 00/50391 (2000-08-01), None
patent: WO 01/81308 (2001-11-01), None
patent: WO 02/02554 (2002-01-01), None
patent: WO 02/24649 (2002-03-01), None
patent: WO 03/066592 (2003-08-01), None
patent: WO 03/216380 (2003-11-01), None
patent: WO 2004/101562 (2004-11-01), None
patent: WO 2005/028440 (2005-03-01), None
Bancher, C., et al., “Low prevalence of apolipoprotein E ∈4 allele in the neurofibrillary tangle predominant form of senile dementia”, Springer, 128:46764 (1997).
Beal, M., et al., “Degnerative Diseases of the Nervous System”, Harrison's Principals of Internal Medicine, 12thEdition, 1991.
Butcher, J., “Alzheimer's amyloid hypothesis gains support”, Science and Medicine, The Lancet, vol. 356, p. 2161, (2000).
Chui, et. al., “Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid”, Nature America, 131:86371 (1999).
Fortini, M., “γ-Secretase-mediated Proteolysis in Cell-Surface-Receptor Signalling”, Nature Reviews/Mol. Cell. Biol. vol. 3 pp. 673-684 (2002).
Goto, G., et al., “Preparation of five-membered heterocyclic amide derivatives” 118:213064 (1993).
Hansen, H., et al., “Multistep Solution-Phase Parallel Synthesis of Spiperone Analogues”, Bioorganic & Medicinal Chemistry Letters, vol. 10, pp. 2435-2439 (2000).
Hardy, J., et al., “The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics”, Science's Compass Review, vol. 297 pp. 353-356 (2002).
Hock, C., et al., “Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Diesease”, Neuron, vol. 38, pp. 547-554 (2003).
Hooper, N., et al., “Membrane Protein Secretases”, Portland Press, 126:196601 (1997).
Leblanc., A., et al., “Production of Alzheimer 4kDa β-amyloid peptide requires the C-terminal cytosolic domain of the amyloid precursor protein”, Academic, 121:298388 (1994).
MacPherson, L., et al., “Arylsulfonamido-substituted hydroxamic acids”, U.S., 31 pp., Cont.-in-part of U.S. 5,552,419, 127:162116 (1997).
Nielsen, S., et al., “Novel Potent Ligands for the Central Nicotinic Acetylcholine Receptor: Synthesis, Receptor Binding, and 3D-QSAR Analysis”, J. Med. Chem. vol. 43, No. 11, pp. 2217-2226 (2000).
Obici, L., et al., “A novel AβPP Mutation Exclusively Associated with Cerebral Amyloid Angiopathy”, Ann. of Neurology, vol. 58, No. 4, pp. 639-644 (2005).
Pear, W., et. al., “T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling”, Curr. Opin. Hematology, vol. 11(6), pp. 426-433 (2004).
Takefumi, M., et al., Reaction of N-Benzenesulfonyl-9-Azabicyclo-[3.3.1]Nona-2,6-Diene with Diborane: Failure of Cyclic Hydroboration in the Intramolecularly Faced Diene System,Heterocyclesvol. 6, No. 4 (1977) 469-474.
Wang, H., “High-performance liquid chromatographic analysis of 6β-acetoxynortropane eye drops”, 116:91540 (1992).
Xia, W., “Relationship between presenilinase and γ-secretase”, Prous Science, 139:357800 (2003).
PCT International Search Report dated Sep. 28, 2005 for PCT Application No. PCT/US2005/011456.
PCT International Search Report dated Dec. 22, 2004 for PCT Application No. PCT/US2004/014671.
English abstract for FR2802206, Jun. 15, 2001.
English abstract for JP 4-247081, Sep. 3, 1992.
STN Registry No. 401648-55-3, Mar. 18, 2002.
Kreier, A., et al., Asymmetric Synthesis of Stereodefined 7-(Alk-1-enyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic Acids and Their Precursors, Bearing a Polar Group in the 8-Position, by the 3-Sulfonyl-1,3-oxazolidine Method, Synthesis 2000, No. 10, 1391-1402.
Steif, F., et al., Enantio- and Diastereoselective Synthesis of (Protected) 2-Formyl-and 2-(Hydroxymethyl)-1-phenylalkane-1,3-diols from Chiral 2-Methoxy-3-tosyl-1,3-oxazolidines by Subsequent Asymmetric Formylation and Aldolization, Synthesis 2000, No. 5, 743-753.
Almstead, N., et al., Design, Synthesis, and Biological Evaluation of Potent Thiazine- and Thiazepine-Based Matrix Metalloproteinase Inhibitors, J. Med. Chem. 1999, 42, 4547-4562.
Teall, M., et al., Aryl sulfones: a new class of γ-secretase inhibitors, Bioorganic & Medicinal Chemistry Letters 15 (2005) 2685-2688.
PCT International Search Report dated Nov. 2, 2006, for corresponding PCT Application No. PCT/US2005/023187.
Bara Thomas A.
Clader John W.
Josien Hubert B.
Li Hongmei
Pissarnitski Dmitri A.
Anderson Rebecca
Devlin Gerard M.
Hess Susan L.
Jeanette Henry C.
Schering Corporation
LandOfFree
Substituted N-arylsulfonylheterocyclic amines as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted N-arylsulfonylheterocyclic amines as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted N-arylsulfonylheterocyclic amines as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683833